In our study, for the first time, we assessed the impact of TLR3/4-primed-MSCs-CMs on anti-tumour activities of MSCs in a time and dose-dependent manner by focusing on induced-apoptotic components cell signalling pathways and compared MSCs phenotypes (MSC-1 and MSC-2) on the GBM cell line. The gene discussed is TLR3; the disease is neoplasm.